Canada markets open in 2 hours 52 minutes
  • S&P/TSX

    20,700.50
    +100.90 (+0.49%)
     
  • S&P 500

    4,060.43
    +44.21 (+1.10%)
     
  • DOW

    33,949.41
    +205.57 (+0.61%)
     
  • CAD/USD

    0.7507
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    82.40
    +1.39 (+1.72%)
     
  • BTC-CAD

    30,584.74
    -189.41 (-0.62%)
     
  • CMC Crypto 200

    520.23
    -6.96 (-1.32%)
     
  • GOLD FUTURES

    1,931.00
    +1.00 (+0.05%)
     
  • RUSSELL 2000

    1,903.06
    +12.75 (+0.67%)
     
  • 10-Yr Bond

    3.4930
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,041.75
    -65.00 (-0.54%)
     
  • VOLATILITY

    18.89
    -0.19 (-1.00%)
     
  • FTSE

    7,772.71
    +11.60 (+0.15%)
     
  • NIKKEI 225

    27,382.56
    +19.81 (+0.07%)
     
  • CAD/EUR

    0.6895
    +0.0004 (+0.06%)
     

Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)

If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. So when we looked at STAAR Surgical (NASDAQ:STAA) and its trend of ROCE, we really liked what we saw.

Understanding Return On Capital Employed (ROCE)

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. Analysts use this formula to calculate it for STAAR Surgical:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.14 = US$50m ÷ (US$395m - US$45m) (Based on the trailing twelve months to September 2022).

So, STAAR Surgical has an ROCE of 14%. In absolute terms, that's a satisfactory return, but compared to the Medical Equipment industry average of 11% it's much better.

See our latest analysis for STAAR Surgical

roce
roce

Above you can see how the current ROCE for STAAR Surgical compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free report on analyst forecasts for the company.

So How Is STAAR Surgical's ROCE Trending?

We're delighted to see that STAAR Surgical is reaping rewards from its investments and is now generating some pre-tax profits. Shareholders would no doubt be pleased with this because the business was loss-making five years ago but is is now generating 14% on its capital. And unsurprisingly, like most companies trying to break into the black, STAAR Surgical is utilizing 643% more capital than it was five years ago. This can tell us that the company has plenty of reinvestment opportunities that are able to generate higher returns.

On a related note, the company's ratio of current liabilities to total assets has decreased to 11%, which basically reduces it's funding from the likes of short-term creditors or suppliers. So this improvement in ROCE has come from the business' underlying economics, which is great to see.

What We Can Learn From STAAR Surgical's ROCE

Overall, STAAR Surgical gets a big tick from us thanks in most part to the fact that it is now profitable and is reinvesting in its business. And a remarkable 253% total return over the last five years tells us that investors are expecting more good things to come in the future. With that being said, we still think the promising fundamentals mean the company deserves some further due diligence.

Before jumping to any conclusions though, we need to know what value we're getting for the current share price. That's where you can check out our FREE intrinsic value estimation that compares the share price and estimated value.

While STAAR Surgical isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here